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Abstract
Mutations in APC/β-catenin resulting in an aberrant activation of Wnt/β-catenin pathway are common in colorectal
cancer (CRC), suggesting that targeting the β-catenin pathway with chemopreventive/anticancer agents could be a
potential translational approach to control CRC. Using human CRC cell lines harboring mutant (SW480) versus wild-
type (HCT116) APC gene and alteration in β-catenin pathway, herein we performed both in vitro and in vivo studies
to examine for the first time whether silibinin targets β-catenin pathway in its efficacy against CRC. Silibinin treatment
inhibited cell growth, induced cell death, and decreased nuclear and cytoplasmic levels of β-catenin in SW480 but not
in HCT116 cells, suggesting its selective effect on the β-catenin pathway and associated biologic responses. Other stud-
ies, therefore, were performed only in SW480 cells where silibinin significantly decreased β-catenin–dependent T-cell
factor-4 (TCF-4) transcriptional activity and protein expression of β-catenin target genes such as c-Myc and cyclin D1.
Silibinin also decreased cyclin-dependent kinase 8 (CDK8), a CRC oncoprotein that positively regulates β-catenin activity,
and cyclin C expression. In a SW480 tumor xenograft study, 100- and 200-mg/kg doses of silibinin feeding for 6 weeks
inhibited tumor growth by 26% to 46% (P < .001). Analyses of xenografts showed that similar to cell culture findings,
silibinin decreases proliferation and expression of β-catenin, cyclin D1, c-Myc, and CDK8 but induces apoptosis in vivo.
Together, these findings suggest that silibinin inhibits the growth of SW480 tumors carrying the mutant APC gene by
down-regulating CDK8 and β-catenin signaling and, therefore, could be an effective agent against CRC.
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Introduction
According to the American Cancer Society, 106,100 and 40,870 new
cases of colon and rectal cancers would have occurred in the United
States in 2009 alone, respectively. Although the incidence of colorectal
cancer (CRC) has decreased during the last two decades, still it accounts
for 9% of total deaths caused by cancer of all other sites [1]. Screening
of adults older than 50 years has contributed significantly in reducing
CRC incidence [2–4]; however, significant mortality and morbidity are
still associated with clinically advanced CRC cases. Similarly, there is
sufficient evidence that use of nonsteroidal anti-inflammatory drugs
including aspirin and other cyclooxygenase-2 inhibitors is effective in
reducing the risk of CRC [5]; however, the success of such strategies is
limited by associated toxicities and adverse effects including gastro-
intestinal bleeding, kidney failure, etc. [5]. These limitations argue the
need for the identification of mechanism-based new agents that could
be useful for effective chemopreventive and/or interventional strategies
against CRC.
Because genetic predispositions and lifestyle are twomajor risk factors
for CRC [6,7], the latter one provides an opportunity to control the risk
by changing daily habits. In lifestyle risk factors, dietary habits have
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considerable role where diets rich in fat (such as red meat) and high
calories are associated with a high risk of developing CRC and those rich
in fruits and vegetables have been associated with lower risk [6]. Al-
though no conclusive studies are available in literature in this regard
[8–10], fruits and vegetables not only are considered a good source of
fiber, vitamins, and other nutrients, which may contribute in prevent-
ing the occurrence of CRC, but also contain nonnutrient phytochemi-
cals with significant chemopreventive potential. To date, many food/
plant–derived chemopreventive agents that exhibit strong efficacy
against various cancers in in vitro and preclinical models have been iden-
tified [11–14]. We have shown that silibinin, an active ingredient of
the commonly used health supplementmilk thistle (Silybummarianum)
extract, exhibits anticancer/chemopreventive efficacy in different in vivo
and in vitromodels of various cancers, including CRC [15–22]. Impor-
tantly, silibinin is largely nontoxic and is well tolerated without causing
any adverse effects when given up to a dose of 1% in diet or 750 mg/kg
body weight in our previously completed studies in rodents [15–22].
Aberrant Wnt signaling has been reported to contribute to various
human diseases including CRC [23]. Wnt signaling pathway plays a
central role in numerous cellular processes starting from embryonic de-
velopment to tissue/organ homeostasis in adults. β-Catenin is a key
component of this pathway, performing a dual function, being a compo-
nent of cell-cell adhesion and a transcriptional activator in conjunction
with T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription
factors [24]. The cellular levels of β-catenin are tightly regulated by a
multiprotein destruction complex consisting of adenomatous polyposis
coli (APC), axin, and glycogen synthase kinase 3β (GSK-3β) [25]. Aber-
rant activation of β-catenin, mostly due to mutation(s) in APC, confers
oncogenic potential by activating several target genes of the Wnt/
β-catenin pathway such as cyclin D1, c-Myc, etc. [26]. Germ line muta-
tions in the APC gene are seen in patients whose conditions have been
diagnosed as familial adenomatous polyposis or CRC [27]. In addition,
activating mutations in β-catenin involving exon 3 occur in less than 5%
of CRC [28,29]. Overall, an aberrant activation of β-catenin–dependent
signaling has a major contribution in the pathogenesis of CRC, and
therefore, targeting this pathway might have vital implications in con-
trolling the progression of this malignancy. Herein, we studied the pos-
sible efficacy and associated mechanisms of silibinin against the human
colorectal carcinoma SW480 cell line that harbors mutation in the APC
gene [30] as well as in the HCT116 cell line. For the first time, we show
that, in comparison to HCT116 cells, silibinin selectively inhibits the
growth of SW480 cells in vitro as well as in vivo through the down-
regulation of β-catenin signaling.
Materials and Methods
Reagents
TCF-luciferase reporter plasmids (8× TOP/FOP FLASH) were gen-
erously provided by Randall Moon (University of Washington, School
of Medicine, Seattle, WA). Antibodies against cyclin-dependent ki-
nase 8 (CDK8), cyclins C and D1, β-catenin, and c-Myc were from
Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-
proliferating cell nuclear antigen (PCNA) antibody was from Dako
(Carpinteria, CA). Silibinin and anti–β-actin antibody were from Sigma-
Aldrich (St Louis, MO). Antibody against glutathione-S -transferase pi
(GST-π)was fromMedical andBiological LaboratoriesCo, Ltd (Woburn,
MA). Anti–histone H1 antibody was from Neomarkers (Fremont, CA).
Alexa Fluor 488–tagged goat antirabbit antibody was from Invitrogen
Corporation (Carlsbad, CA).
Cell Culture and Cell Viability Assay
SW480 and HCT116 cells were procured from American Type
Culture Collection (Manassas, VA) and maintained in Leibovitz me-
dium and Dulbecco’s modified Eagle medium, respectively, supple-
mented with 10% FBS and 100 U/ml of penicillin and streptomycin
under standard culture conditions. Cells were cultured at a density of
5000 cells/cm2 in 60-mm dishes and were treated the following day
with either DMSO alone or silibinin (50-200 μM) in DMSO for
24 to 72 hours, and both adherent and nonadherent cells were collected
by brief trypsinization followed by centrifugation. Cells were stained
with Trypan blue and counted as live (unstained) and dead (blue-
colored) cells using hemocytometer under a light microscope.
Western Immunoblot Analysis
At the end of treatments, total cell lysates were prepared in non-
denaturing lysis buffer as described previously [31]. In some experiments,
after treatments, nuclear and cytoplasmic fractions were prepared as
described earlier [31]. Total cell lysates (50-70 μg) and nuclear or cyto-
plasmic fraction (5-15 μg) proteins were denatured in 2× sample buffer
and subjected to sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis on 8%, 12%, or 16% Tris–glycine gel [16,19]. To ensure
equal protein loading, each membrane was stripped and reprobed with
anti–β-actin (total cell lysates), anti–GST-π (cytosolic), or histone H1
(nuclear) antibody to normalize for differences in protein loading and
to establish the purity of the cytoplasmic and nuclear fractions.
Immunofluorescence Confocal Microscopy
SW480 cells were plated on coverslips overnight and then treated
with either DMSO or silibinin (100 μM) in DMSO for 48 hours.
At the end of treatment time, cells grown on the coverslips were washed
gently with PBS and fixed in 3% formaldehyde for 10 minutes. Cells
on the coverslips were again washed twice with PBS, incubated with
Triton X-100 for 5 minutes, and later washed twice with PBS followed
by a final wash with TBST (10 mMTris-HCl, pH 8.0, 150 mMNaCl,
0.2% vol/vol Tween-20). Cells were incubated in Leibovitz complete me-
dium for 3 to 4 hours followed by β-catenin antibody for overnight. Fi-
nally, cells were incubated (45minutes) withAlexa Fluor 488–tagged goat
antirabbit secondary antibody and counterstained with 4′,6′-diamidino-
2-phenylindole (DAPI) for 5minutes. Cell images were captured at 1000×
magnification on a Nikon D Eclipse C1 confocal microscope (Nikon,
Instruments Inc., Melville, NY), and images were processed by EZ-C1
Freeviewer software.
TOP/FOP FLASH Activity
SW480 cells were plated at a confluence of 40% to 50% in 60-mm
dishes overnight. The cells were transfected with 1 μg of 8× TOP/FOP
FLASH plasmid DNA along with 0.3 μg of pRL-CMV plasmid using
Mirus transfection reagent. After 24 hours of transfection, cells were
treated with either DMSO or silibinin (100 μM) inDMSO for another
24 hours, and luciferase activity was measured using the Dual Lucif-
erase Reporter Assay System (Promega, Madison, WI). Transfection
efficiency was normalized using renilla luciferase activity. Experiments
were done at least three times, and the data are shown from a represen-
tative experiment.
Experimental Design for Tumor Xenograft Study
Six-week-old athymic (nu/nu) male nude mice were obtained from
the National Cancer Institute (Bethesda, MD), housed under standard
laboratory conditions, and fed autoclaved AIN-76A rodent diet (Dyets,
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Inc, Bethlehem, PA) and water ad libitum. The protocol for conducting
this study was approved by the Institutional Animal Care and Use
Committee of the University of Colorado Denver. Mice were sub-
cutaneously injected with exponentially growing 5 × 106 SW480
cells mixed with Matrigel (1:1) in the right flank to initiate tumor
growth and then divided into three groups, each having eight mice.
After 24 hours, mice in control (first) group were gavaged with vehicle
(0.2 ml of 0.5% [wt/vol] carboxymethyl cellulose [CMC] in saline per
day), whereas animals in the second and third groups were gavaged
with 100 and 200 mg/kg body weight doses of silibinin in vehicle, re-
spectively, 5 days/week for 6 weeks. Body weight and diet consumption
were recorded twice weekly throughout the study. After tumors started
growing, their sizes were measured twice weekly using digital vernier
caliper. Tumor volume was calculated by using the formula 0.5236L1
(L2)
2, where L1 is long axis and L2 is the short axis of the tumor. At the
end of the experiment, mice were killed, and tumors were excised,
weighed, and fixed in buffered formalin for further analysis.
Immunohistochemical Staining for PCNA, Cyclin D1,
c-Myc, CDK8, and β-Catenin
Tumor tissues fixed in 10%phosphate-buffered formalin for 12 hours
were routinely processed for paraffin-embedded 4-μm sections and
immunohistochemical (IHC) staining. Briefly, sections were subjected
to antigen-retrieval, quenched of endogenous peroxidase activity [15],
and then incubated with anti-PCNA (1:400 dilutions), anti–cyclin D1
(1:200 dilutions), anti–c-Myc (1:100 dilutions), anti-CDK8 (1:100
dilutions), or anti–β-catenin (1:100 dilutions) antibodies in a hu-
midity chamber. Few sections were incubated with N-Universal Nega-
tive Control antibody under identical conditions. The sections were
then incubated with an appropriate biotinylated secondary antibody
followed by HRP-conjugated streptavidin and 3,3′-diaminobenzidine
and counterstained with Harris hematoxylin. Quantification was done
by counting brown colored positive cells and total number of cells
at five arbitrarily selected fields in each sample at 400× magnification.
Terminal Deoxynucleotidyl Transferase–Mediating dUTP
Nick End Labeling Staining for Apoptotic Cells
Apoptotic cells were detected by terminal deoxynucleotidyl transferase–
mediating dUTP nick end labeling (TUNEL) staining using Dead
End Colorimetric TUNEL system (Promega) following the vendor’s
protocol. The apoptosis was evaluated by counting TUNEL-positive
cells (brown-stained) as well as the total number of cells in five ran-
domly selected fields in each sample at 400× magnification.
Statistical and IHC Analyses
All statistical analyses were carried out with Sigma Stat software
version 3.5 ( Jandel Scientific, San Rafael, CA). Statistical significance
of difference between the control and treated groups was determined
either by Student’s t-test or one-way analysis of variance followed by
Bonferroni t-test. P < .05 was considered statistically significant. IHC
analyses were done with a Zeiss Axioskop 2 microscope (Carl Zeiss,
Inc, Jena, Germany). Microscopic images were taken by AxioCam
MrC5 camera at 400× magnification and processed by AxioVision soft-
ware documentation system (Carl Zeiss, Inc). Western blots were
scanned with Adobe Photoshop 6.0 (Adobe Systems, Inc, San Jose,
CA), and densitometric analysis was then done using Scion Image Pro-
gram (National Institutes of Health, Bethesda, MD). The densitometry
data are shown below each band as fold change with respective control.
Results
Silibinin Inhibits the Growth of Human CRC SW480 Cells
Treatment of SW480 cells with silibinin (50, 100, and 200 μM
for 24-72 hours) showed a concentration- and time-dependent decrease
in cell growth, where total cell number decreased by 24% to 63% (P <
.001) after 24 hours, by 58% to 80% (P < .001) after 48 hours, and by
76% to 90% (P < .001) after 72 hours of 50 to 200 μM silibinin treat-
ment, respectively (Figure 1A). Importantly, a considerable cell death
was observed only at the highest concentration (200 μM) of silibinin
accounting for 55% to 85% (P < .001) cell death after 24 to 48 hours
of treatment (Figure 1B). However, after 72 hours of treatment, an
increase in cell death was also observed at 100- (29% cell death) and
200-μM (89% cell death) concentrations of silibinin (Figure 1B). The
cell death by silibinin at higher concentration/s and/or longer treat-
ment time was apoptotic in nature (data not shown). To further
examine the molecular mechanism of the growth-inhibitory effect of
silibinin, we used only 50- and 100-μM silibinin concentrations, which
were not cytotoxic.
Silibinin Decreases Total β-Catenin Levels and Inhibits
Nuclear Translocation of β-Catenin
Because we observed that silibinin exerts a strong inhibitory effect on
the growth of SW480 cells, we next studied whether it is mediated
through modulation of the β-catenin pathway, which is aberrantly
activated in this cell line. Silibinin treatment decreased total cellular
pool of β-catenin in SW480 cells with a more prominent effect at 48
and 72 hours than at 24 hours (Figure 2A). To further confirm that
Figure 1. Silibinin inhibits the growth of human CRC SW480 cells.
Cells were plated overnight and treated with 50 to 200 μM silibinin
for 24 to 72 hours. At the end of treatment, cells were collected
and counted on a hemocytometer after staining with Trypan blue
dyeunder themicroscope for (A) total cell number (live anddeadcells
together) and (B) dead cells represented as percent dead cells. Data
shown aremean±SD. *P< .001 comparedwith the control. SB indi-
cates silibinin.
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Figure 2. Silibinin selectively decreases the total, cytoplasmic, and nuclear pools of β-catenin in human CRC SW480 cells. Cells were plated
overnight and treatedwith 50 to 100μMsilibinin for 24 to 72hours. At the end of treatment, SW480 (A) andHCT116 (B) cellswere analyzed for
total β-catenin levels byWestern immunoblot analysis. HCT116 cells were also analyzed for the total cell number after these treatments (B),
and the data shown are mean ± SD. $P < .05 compared with the control. (C) In separate studies, after similar treatments of SW480 cells,
cytoplasmic and nuclear fractions were prepared and analyzed for β-catenin levels by Western immunoblot analysis. Membranes were re-
probedwith histone H1 (N , nuclear fraction) or GST-π (C , cytoplasmic fraction) as loading controls and asmarkers for purity of the fractions.
Densitometry data shown below each band represent fold change compared with the control after normalization with respective loading
controls. (D) Cellular localization of β-catenin was also observed by immunofluorescent staining followed by confocal imaging. For this,
SW480 cells grown on coverslips were treated with either DMSO alone (control) or 100 μM silibinin for 48 hours, fixed, and stained for
β-catenin (red) or nuclei with DAPI (blue). Original magnification, ×1000.
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the growth-inhibitory effect of silibinin is specifically through down-
regulation of β-catenin levels and associated downstream signaling,
we extended our study to another human CRC cell line, HCT116,
which harbors wild-type APC but mutant β-catenin. We found that
treatment of HCT116 cells with 50 and 100 μM silibinin (24-72 h)
does not produce any measurable growth-inhibitory effect except at
100 μM concentration, and 72 hours of treatment time showing
∼38% decrease (Figure 2B) is contrary to its strong growth-inhibitory
effect seen in SW480 cells (Figure 1A). Furthermore and more impor-
tantly, Western blot analysis revealed that silibinin treatment does not re-
duce β-catenin level inHCT116 cells (Figure 2B) as opposed to its strong
effect in SW480 cells (Figure 2A). These observations clearly suggested
an association between the growth-inhibitory activity of silibinin and a
decrease in β-catenin level selectively in SW480 cells, and accordingly,
we focused our efforts on this aspect only in SW480 cells.
Because nuclear translocation of β-catenin is required for its tran-
scriptional activity, we next studied the effect of silibinin on nuclear
translocation of β-catenin. In Western blot analysis, we observed a
striking decrease in the nuclear level of β-catenin after silibinin treat-
ment at both concentrations and at all three time points studied (Fig-
ure 2C ), together with a decrease in its cytoplasmic level but only
after 48 and 72 hours of treatment. GST-π and histone H1 levels
were also analyzed to check the purity of the cytoplasmic and nuclear
fractions as well as protein loading, respectively (Figure 2C ), and the
fold change numbers shown below the bands are after correcting for
these loading controls. We further confirmed our results about the
effect of silibinin in decreasing both the cytoplasmic and nuclear
β-catenin levels by immunocytochemical analysis for cellular distribu-
tion of β-catenin. As shown in Figure 2D, silibinin-treated SW480
cells (48 hours) showed overall lesser immunofluorescence (red ) for
β-catenin (in both cytoplasm and nucleus) compared with an intense
β-catenin staining observed in the cytoplasm as well as in the nucleus of
control cells.
Silibinin Inhibits β-Catenin–Dependent Transcriptional
Activity and Decreases the Expression of CDK8 and
Downstream β-Catenin–Transcriptional Targets
To study the effect of silibinin on the transactivation function of
β-catenin, SW480 cells were transiently transfected with TOP/FOP
FLASH reporter constructs that contain eight wild-type or mutant
TCF/LEF binding sites upstream of the Luciferase gene. The reporter
activity was significantly (P < .05) inhibited by 100 μM silibinin after
24 hours of treatment (Figure 3A), suggesting that silibinin inhibits
β-catenin–mediated transcriptional activity. A marginal nonspecific
inhibitory effect of silibinin (25% decrease or 0.75 FOP FLASH ratio
of control and silibinin treatment) on FOP FLASH reporter activity
was also observed (Figure 3A). Recently, it has been shown that tran-
scriptional activity of β-catenin is regulated by CDK8 and cyclin C, of
which CDK8 works as an oncogene in CRC [32]. We, therefore, also
examined the protein levels of both CDK8 and cyclin C. Silibinin
treatments reduced CDK8 level in a concentration-dependent manner
at all three time points of 24 to 72 hours; however, a decrease in cyclin
C level was observed only at 72 hours of treatment (Figure 3B). Thus,
a decrease in the CDK8 level by silibinin might be an additional con-
tributory mechanism in its inhibitory effect on β-catenin–mediated
transcriptional activity. In other studies examining the effect of silibinin
on the levels of downstream target proteins (cyclin D1 and c-Myc) of
β-catenin signaling, silibinin reduced the protein levels of both cyclin
D1 and c-Myc in both concentration- and time-dependent manners
(Figure 3B).
Silibinin Suppresses Human CRC SW480 Tumor Xenograft
Growth in Nude Mice
To translate our above in vitro findings in to in vivo biologic relevance,
next we evaluated the effect of silibinin on SW480 tumor xenograft
growth in athymic nude mice. Oral gavage feeding of silibinin at 100
and 200 mg/kg body weight doses, 5 days/week for 6 weeks, caused a
marked time-dependent inhibition of xenograft growth in comparison
to vehicle control (Figure 4A). At the end of the experiment, tumor
volume was reduced from 2715 mm3 per mouse in the control group
to 2015 and 1463 mm3 per mouse in the 100- and 200-mg/kg body
weight silibinin treatment groups, which accounted for 26% and
46% decreases, respectively (P < .001; Figure 4A). Consistent with these
results, silibinin treatments also showed a reduction in tumor weight
Figure 3. Silibinin inhibits β-catenin–mediated transcriptional activ-
ity and the expression of its target genes in human CRC SW480
cells. (A) Cells were plated to 40% to 50% confluence overnight
and transfected with 1 μg of TOP/FOP FLASH plasmid constructs
alongwith 300 ng of pRL-CMV plasmid for 24 hours and then treated
with DMSO alone (control) or 100 μM silibinin for another 24 hours.
Luciferase activity was measured using Dual Luciferase Assay kit
(Promega) following the manufacturer’s instruction. Data shown
represent mean ± SD of three independent observations. (B) Cells
were plated overnight and treated with 50–100 μM silibinin for 24 to
72 hours. Total cell lysates were then analyzed byWestern immuno-
blot analysis for CDK8, cyclin C, cyclin D1, and c-Myc levels. Mem-
branes were reprobed with β-actin as loading control. Densitometry
data shown below each band represent fold change compared with
control after normalization with respective loading controls (β-actin).
$P < .05 compared with control.
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by 29% and 52% (P < .05 to P < .01), respectively (Figure 4B). Silibinin
feeding did not show any gross signs of toxicity or possible adverse ef-
fects assessed in body weight gain and diet consumption profiles, dur-
ing 6 weeks of experiment (Figure 4, C andD). Together, these results
demonstrate in vivo antitumor efficacy of oral silibinin feeding against
CRC SW480 tumor xenografts without any apparent signs of toxicity.
Silibinin Inhibits Cell Proliferation and Induces Apoptosis
in Human CRC SW480 Tumor Xenografts
We next investigated the mechanism/s underlying the in vivo anti-
cancer efficacy of silibinin by IHC analysis for PCNA, a marker for cell
proliferation, and TUNEL, a marker for apoptotic response (Figure 5).
Microscopic examination of tumor xenograft sections clearly showed a
decreased immunoreactivity for PCNA in the silibinin-treated groups
compared with the vehicle control (Figure 5A). Quantification of
PCNA-positive cells showed 38% and 49% (P < .001) decreases in pro-
liferation indices in silibinin-treated (100 and 200 mg/kg body weight)
groups compared with vehicle control (Figure 5B). In case of apoptosis,
as shown in the representative photographs, tumor xenografts from
the silibinin-fed groups showed a marked increase in TUNEL-positive
cells compared with the control group (Figure 5C ). Quantification of
TUNEL-stained samples showed five- to six-fold increases (P < .001)
in the number of TUNEL-positive cells in the silibinin-treated groups
compared with the control group (Figure 5D). Together, these results
clearly show both antiproliferative and proapoptotic effects of silibinin
in SW480 tumor xenografts as two major biologic end point mecha-
nisms in its overall anticancer efficacy.
Silibinin Decreases β-Catenin, Cyclin D1, c-Myc, and CDK8
Expression in Human CRC SW480 Tumor Xenografts
Overexpression of β-catenin and its downstream target proteins is
commonly observed in both experimental and human CRCs. To ascer-
tain an in vivo effect of silibinin on the expression of β-catenin and its
downstream target molecules, SW480 xenograft tissues from control
and silibinin-treated groups were also analyzed by IHC staining for
β-catenin, cyclin D1, and c-Myc protein levels. Silibinin-treated (100
and 200 mg/kg body weight) xenografts showed 37% and 43% (P <
.01) decreases in the number of β-catenin–positive cells compared with
vehicle control (Figure 6A). A similar effect of silibinin on cyclin D1
expression was also observed where it caused 39% and 52% (P <
.001) decreases in cyclin D1–positive cells at two dose levels compared
with control (Figure 6B). In case of c-Myc expression, the percentage of
c-Myc–positive cells was reduced by 33% and 39% (P < .01 to P <
.001) by these silibinin treatments (Figure 6C). Next, we studied the
effect of silibinin on CDK8 expression, which regulates β-catenin–
mediated transcriptional activity and seems to be one of the molecular
targets of silibinin action in SW480 cells in our cell culture studies. IHC
analysis of xenografts showed that silibinin treatment also significantly
Figure 4. Silibinin treatment inhibits human CRC SW480 xenograft growth in athymic nude mice. Mice were subcutaneously injected
with SW480 cellsmixedwithMatrigel and, after 24 hours, gavagedwith CMC (control group) or 100 (SB-100) and 200mg/kg bodyweight/day
doses (SB-200) of silibinin for 5 days/week for 6 weeks. (A) Tumor volume/mouse as a function of time, (B) tumorweight/mouse at the end of
study, (C) average body weight/mouse, and (D) average diet consumption/mouse/day were analyzed as detailed in Materials and Methods.
Data shown in panels A and B are mean ± SE from eight mice in each group.
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decreases CDK8-positive cells by 22% and 40% (P < .05 to P < .001) at
two dose levels compared with vehicle control (Figure 6D). Together,
these findings suggest that down-regulation of β-catenin levels and
consequent signaling could be a potential in vivo mechanism by which
silibinin inhibits SW480 tumor growth in nude mice.
Discussion
CRC is considered as one of the preventable malignancies because life-
style is one of the major factors that could be changed. Although the
incidence of CRC has shown decline in recent years and 5-year survival
rate is 90% when diagnosed at an early and localized stage, the chances
of diagnosis at this stage is only 39% [1]. Therefore, apart from screen-
ing and early diagnosis in a high-risk population, various preventive
measures such as maintaining healthy lifestyle and chemoprevention
strategies are expected to cause a great impact on lowering the incidence
of this malignancy. Chemopreventive strategies on the basis of relatively
nontoxic agents are required in light of increased cardiovascular risk
and other upper gastrointestinal adverse effects with prolonged use of
nonsteroidal anti-inflammatory drugs as chemopreventive agents [5].
Naturally occurring agents might serve as nontoxic alternatives to
these drugs as chemopreventive agents for long-term use in high-risk
targeted CRC patient population. In the present study, we studied the
efficacy of silibinin, an active constituent of milk thistle extract that
is traditionally used for curing hepatic ailments and has also shown che-
mopreventive efficacy against various epithelial malignancies in nu-
merous in vitro and preclinical models [14–22,33,34]. In previously
published studies, we demonstrated the anticancer/chemopreventive
efficacy of silibinin against human colorectal carcinoma HT-29 and
LoVo cells, which represent early developmental and advanced meta-
static stages of CRC, respectively [15,16]. However, the effect of sili-
binin on the β-catenin pathway in CRC is largely unknown. Herein,
we conducted a detailed mechanistic study to evaluate the efficacy of
silibinin against human CRC using human CRC SW480 cells in vitro
and in vivo. This cell line represents the advanced stage (Duke type B)
of CRC and harbors mutant APC and wild-type β-catenin. Because
APC is most frequently mutated in most cases of CRC followed by
mutations in β-catenin, the selection of this cell line provided us the
tool to gain an insight into targeting of β-catenin signaling by silibinin
in its anticancer efficacy against CRC.
APC and β-catenin proteins are important players in Wnt/β-catenin
pathway, which is often deregulated in CRC [35]. β-Catenin is a key
protein in the canonical Wnt pathway where it acts as a transcriptional
coactivator and affects the expression of genes involved in cell pro-
liferation, differentiation, and survival [26]. Because it is involved in
the maintenance of cellular homeostasis, both intracellular pool and
subcellular localization of β-catenin are critically maintained. In the
absence of the Wnt signal, the cytoplasmic pool of β-catenin is main-
tained at a low level and is regulated by three different pathways. The
first canonical pathway involves multiprotein destruction complex,
consisting of GSK-3β, casein kinase 1, APC, and axin, which targets
β-catenin for proteasomal degradation [36]; the second pathway
involves p53/Siah1 [37]; and the third pathway involves nuclear
hormone receptor–mediated degradation of β-catenin [38]. APC gene
Figure 5. Silibinin treatment inhibits cell proliferation and induces apoptosis in human CRC SW480 xenograft. Xenograft tumor tissues
were analyzed for PCNA- and TUNEL-positive cells. Representative photographs for IHC staining of PCNA-positive (A) and TUNEL-positive (C)
cells in tumor tissue from the vehicle control and silibinin-fed groups, respectively, are shown at 400× magnification. (B) Percent PCNA
labeling index and (D) percent TUNEL-positive apoptotic cells in tissues were analyzed as detailed in Materials and Methods. Data shown
represent mean ± SE from eight mice in each group. SB-100 and SB-200 indicates 100 and 200 mg/kg body weight silibinin, respectively.
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mutations are observed in 70% cases of CRC and are considered as an
initiating event as a consequence of the inability of the destruction
complex to promote degradation of β-catenin [39,40]. In our study,
silibinin significantly inhibited the growth of SW480 cells in culture
without causing any considerable death at lower concentrations (50
and 100 μM). At a molecular level, silibinin decreased the total
cellular pool as well as the subcellular localization of β-catenin. A de-
crease in both cytoplasmic and nuclear localization of β-catenin was
observed on silibinin treatment, which may reflect an overall decrease
in the cellular pool of β-catenin. At an early treatment time, silibinin
seems to decrease only the nuclear level of β-catenin; however, at later
treatment time points, the effect was evident in both nuclear and cyto-
plasmic compartments. The prominent decrease in nuclear localization
of β-catenin was further corroborated by a decrease in the β-catenin–
mediated transcriptional activity after silibinin treatment. Thus, the
down-regulation of β-catenin/TCF signaling by silibinin seems to exert
an important role in inhibiting the proliferative capacity of CRC cells.
The specificity of the growth-inhibitory effect of silibinin through a de-
crease in β-catenin level and associated downstream signaling was
further supported by the findings where HCT116 cells, which harbor
wild type APC but mutant β-catenin, failed to respond to both growth
inhibition and decrease in β-catenin levels by silibinin.
Recently, Firestein et al. [32] showed that β-catenin transcriptional
activity is positively regulated by the kinase activity of CDK8 and iden-
tified it as a CRC oncogene. They also reported that SW480 cell line
carry gain in copy number for CDK8 gene together with a higher ex-
pression of CDK8 protein. CDK8, along with cyclin C, Med12, and
Med13, forms a “mediator complex” that is involved in the regulation
of transcription [41]. Furthermore,Morris et al. [42] showed thatCDK8
could also indirectly upregulate β-catenin–dependent signaling by
repressing E2F1 activity; E2F1 directly inhibits β-catenin–dependent
transcriptional activity independent of APC/GSK-3β activity. In
our study, silibinin treatment decreased the protein level of CDK8,
which might have, in part, contributed to the observed inhibition of
β-catenin–mediated transcriptional activity by silibinin. Further stud-
ies in future, however, are required to fully illustrate this mechanism.
One of the downstream targets of β-catenin/TCF/LEF transcrip-
tional activity involved in cell cycle regulation is cyclin D1, a key mole-
cule facilitating the progression of cells through the G1 checkpoint
[43,44]. Another downstream target of this pathway is C-Myc, which
is a proto-oncogene that transcriptionally regulates the genes involved
in cell cycle progression (G1-S transition), metabolism, ribosome bio-
genesis, protein synthesis, and apoptosis [45]. We observed a decreased
expression of both cyclin D1 and c-Myc by silibinin, suggesting their
possible role in the observed growth-inhibitory effects of silibinin in
SW480 cells. Recently, it was reported that c-Myc is involved in APC
gene loss–induced phenotypes in intestine [46]. Loss of APC gene
imparts crypt progenitor cell–like phenotype to the intestinal entero-
cytes, which fail to differentiate and migrate to the crypt-villus axis, re-
sulting in enlarged intestinal crypts. However, a combined deletion
of APC and c-Myc genes in adult mouse small intestine results in pro-
liferation, differentiation, and migration of intestinal enterocytes to
Figure 6. Silibinin treatment suppresses β-catenin, cyclin D1, c-Myc, and CDK8 expression in human CRC SW480 xenograft. Xenograft
tumor tissues were analyzed for (A) β-catenin-, (B) cyclin D1-, (C) c-Myc-, and (D) CDK8-positive cells as detailed in Materials and Methods.
Data shown represent mean ± SE from eight mice in each group.
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crypt-villus axis [47]. On the basis of these literature reports, it could be
suggested that the down-regulation of c-Myc protein level by silibinin
might contribute to its efficacy against CRC.
To further substantiate in vitro the growth-inhibitory effects of sili-
binin on human CRC SW480 cells, we extended our studies to in vivo
conditions by implanting SW480 tumor xenografts in athymic nude
mice. Silibinin feeding significantly inhibited the growth of SW480
tumor xenografts, which was accompanied by a decrease in the levels
of β-catenin and its downstream targets, cyclin D1 and c-Myc. A down-
regulation in the expression of CDK8 by silibinin treatment was also
observed in these studies, further supporting the notion that CDK8
might be one of the molecular targets of silibinin efficacy. Reduced
PCNA positivity of tumors from silibinin-fed mice confirmed its in vivo
growth-inhibitory effects. We also observed apoptotic cells in tumors
from silibinin-fed mice; therefore, induction of apoptosis by silibinin
may also contribute to its in vivo efficacy.
In recent years, there had been an effort to translate the relevance of
both cell culture and preclinical anticancer efficacy studies into the
clinical settings, specifically those related to a comparable effective dose
in humans. To address the issue of dose translation from one species to
another, calculation of human equivalent dose (HED) using normali-
zation of the body surface area instead of weight has been advocated
[48]. On the basis of the formula proposed for calculating HED, we
found that the corresponding HED for silibinin at the maximum dose
(200 mg/kg body weight of mouse) used in our in vivo study would be
973 mg/60-kg adult. The resultant HED is within the doses used in
CRC patients in the study by Hoh et al. [49] where the patients were
fed with 360 to 1440 mg/day of silipide (a formulation of silibinin
for better bioavailability) for 7 days, and the resultant achievable levels
of silibinin in normal and malignant colorectal tissue (target organ)
were 78 to 141 nmol/g, which is again within the range of 100-μM
concentration of silibinin used in our in vitro experiments. Thus, the
effective in vitro concentrations and in vivo doses of silibinin used in
the present study are within the range of physiologically achievable
concentrations of silibinin in the colon tissue of CRC patients fed with
silibinin doses in line with our animal studies. Collectively, the find-
ings of the present study along with no apparent toxicity associated
with silibinin underscore the efficacy of silibinin against CRC with
translational potential in the future.
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